Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Stopped The study was terminated due to the sponsor's decision to discontinue the clinical trial.

Conditions

• Solid Tumor

Interventions

• DRUG: KITE-718
• DRUG: Cyclophosphamide
• DRUG: Fludarabine
• DEVICE: MAGE - A3/A6 Screening Test

Sponsor

Kite, A Gilead Company